Patrice Degoulet

Patrice Degoulet

Auto-generated profile, based on publicly available information

Patrice Degoulet

Université Paris 5

Research Focus & Metrics

Academic Career Length

54Years (1973-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 1996 in BMJ
Verified
Journal Article
Closed access
GCGilles Chatellier
Gilles Chatellier
EZEric Zapletal
Eric Zapletal
DLDavid Lemaitre
David Lemaitre
JMJoel Menard
Joel Menard
PDPatrice Degoulet
Patrice Degoulet
The number needed to treat is a meaningful way of expressing the benefit of an active treatment over a control. It can be used either for summarising the results of a therapeutic trial or for medical decision making about an individual patient, but its use at the bedside has been impeded by the need for time consuming calculations. A nomogram has therefore been devised that will greatly simplify the calculations. Since calculations are now easy, the number needed to treat can be used to assess the value of several interventions, although it does have its limitations. In particular it should not be used when it is not known whether the relative risk reduction associated with an intervention is constant for all levels of risk, or for periods of time longer than that studied in the original trials. In most medical disciplines the gold standard for evaluating the benefit of an active treatment is the randomised controlled trial. Many obstacles exist, however, to the correct use of the results of clinical trials. Inadequate dissemination of results may, for example, explain the differences between doctors in awareness of key advances in myocardial infarction.1 Another influence on clinicians' views of the effectiveness of treatments may be the way in which the results of therapeutic trials are presented.2 3 4 An informative way of presenting results is the number needed to treat described by Laupacis et al.5 As recently underlined by Cook and Sackett, this very simple index is attractive since the meaning of a sentence such as “20 patients need to be treated to avoid 1 death over a five year period” is easily understood by both doctors and patients.6 Nevertheless, the authors underline that the calculations needed—that is, the multiplying of two numbers followed by the taking of …

1 March 2014 in Briefings in Bioinformatics
Verified
Journal Article
Open access
PDF file
VCVincent Canuel
Vincent Canuel
BRBastien Rance
Bastien Rance
PAPaul Avillach
Paul Avillach
PDPatrice Degoulet
Patrice Degoulet
ABAnita Burgun
Anita Burgun
The rise of personalized medicine and the availability of high-throughput molecular analyses in the context of clinical care have increased the need for adequate tools for translational researchers to manage and explore these data. We reviewed the biomedical literature for translational platforms allowing the management and exploration of clinical and omics data, and identified seven platforms: BRISK, caTRIP, cBio Cancer Portal, G-DOC, iCOD, iDASH and tranSMART. We analyzed these platforms along seven major axes. (1) The community axis regrouped information regarding initiators and funders of the project, as well as availability status and references. (2) We regrouped under the information content axis the nature of the clinical and omics data handled by each system. (3) The privacy management environment axis encompassed functionalities allowing control over data privacy. (4) In the analysis support axis, we detailed the analytical and statistical tools provided by the platforms. We also explored (5) interoperability support and (6) system requirements. The final axis (7) platform support listed the availability of documentation and installation procedures. A large heterogeneity was observed in regard to the capability to manage phenotype information in addition to omics data, their security and interoperability features. The analytical and visualization features strongly depend on the considered platform. Similarly, the availability of the systems is variable. This review aims at providing the reader with the background to choose the platform best suited to their needs. To conclude, we discuss the desiderata for optimal translational research platforms, in terms of privacy, interoperability and technical features.

1 August 2005 in International Journal of Medical Informatics
Verified
Journal Article
Closed access
MBMarie Catherine Beuscart-Zéphir
Marie Catherine Beuscart-Zéphir
SPSylvia Pelayo
Sylvia Pelayo
FAFrançoise Anceaux
Françoise Anceaux
JMJean-Jacques Meaux
Jean-Jacques Meaux
MDMichel Degroisse
Michel Degroisse
PDPatrice Degoulet
Patrice Degoulet

1 June 2016 in Journal of Biomedical Informatics
Verified
Journal Article
Closed access
BHBrahim Hadji
Brahim Hadji
PDPatrice Degoulet
Patrice Degoulet

14 February 2017 in International Journal of Medical Informatics
Verified
Journal Article
Closed access
PDF file
AJAnne-Sophie Jannot
Anne-Sophie Jannot
EZEric Zapletal
Eric Zapletal
PAPaul Avillach
Paul Avillach
MMMarie-France Mamzer
Marie-France Mamzer
ABAnita Burgun
Anita Burgun
PDPatrice Degoulet
Patrice Degoulet

1 October 1981 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
EGE. Gluckman
E. Gluckman
ABA. J. Barrett
A. J. Barrett
william arcesewilliam arcese
william arcese
ADA. Devergie
A. Devergie
PDP. Degoulet
P. Degoulet